From peptide 2° structures to small molecule inhibitors: the Edelris Discovery ENgine (EDEN)

webinar

Wed, 04 Nov 2015, 16:00 CET (Berlin)

Dr. Didier Roche, Edelris France

From peptide 2° structures to small molecule inhibitors: the Edelris Discovery ENgine (EDEN)

Edelris has pioneered for the past decade the design and synthesis of innovative, natural product-like small molecules (Keymical CollectionsTM) and generated its own Keymical SpaceTM representing over 8 M cpds. The EDEN platform (Edelris Discovery ENgine) has been developed to combine the leading role of structural information in drug discovery with the attractiveness of our Keymical SpaceTM in order to design compounds exploring new boundaries in the modulation of biological systems and particularly to address PPIs.

We will present in this webinar the approach used to design compounds mimicking alpha helix peptide secondary structures. 3D-Pharmacophore data mining using ReCore proved to be successful to discover original and drug-like modulators of the MDM2/P53 interaction.

Current news

category
Events
Announcing BioSolveIT's DrugSpace Symposium 2025: Bridging Science
June 26, 2025 09:43 CEST
We are pleased to announce the fourth edition of the BioSolveIT DrugSpace Symposium, taking place on September 24–25, 2025. This year’s theme, “Bridging Science,” highlights the growing importance of interdisciplinary collaboration in driving innovation across the drug discovery landscape. As the field evolves, it becomes increasingly clear that real progress...
Read on
Psst... Are You Following Us Yet? Follow the Science (and a Bit More)
June 25, 2025 08:44 CEST
There’s a lot going on behind the scenes—ideas taking shape, tools evolving, science in motion. And while the website tells you what our software does, our social media gives you a look at how it lives. We’re active on LinkedIn, BlueSky, and YouTube, sharing everything from scientific snapshots to educational...
Read on
AMBrosia Just Got Bigger: 126 Billion Compound Update Now Available
June 11, 2025 13:21 CEST
We are thrilled to announce a major update to the AMBrosia Chemical Space in collaboration with Ambinter! The state-of-the-art source for diverse drug-like scaffolds now boasts an incredible 126 billion of synthetically accessible compounds for drug discovery projects. What does the update feature? Expanded to an astounding 125,924,571,692 compounds (1.26...
Read on